News | Venous Therapies | April 26, 2017

VQI Varicose Vein Registry Yielding Data on Treatment Efficacy

Joint effort of the Society for Vascular Surgery and American Venous Forum was set up to track the outcomes of various treatments for varicose veins

April 26, 2017 — A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the Journal of Vascular Surgery: Venous and Lymphatic Disorders. The registry is a joint effort by the Society for Vascular Surgery, the Vascular Quality Initiative and the American Venous Forum. It was launched in January 2015 and was set up to track systematically the outcomes of various treatments for varicose veins, ultimately providing guidance for both consumers and treating physicians.

“The power in the registry resides in the ability to look at a large and varied data set with importantly defined and relevant physician-generated granular endpoints and patient-reported outcomes (PROs),” said Thomas Wakefield, M.D., who, with lead author Andrea Obi, M.D., developed the journal report.

The journal article, “First 10-month results of the Vascular Quality Initiative Varicose Vein Registry,” by a national team of vascular surgeons, examined the early data. The series included 1,406 patients undergoing venous ablations and phlebectomy. Overall, the reported outcomes were excellent, with significantly improved Clinical classification (CEAP) along with “much improved” Patient Reported Outcomes (PRO). Importantly, the complication rates including infection and venous thrombosis were 1 percent or less.

With governmental incentives for quality reporting, there is a pressing need for data in this evolving field, according to the societies. Although the database is in its early stages, they said it is clear it will bear important fruit for both patients and clinicians looking for the best, proven venous treatments available.

To download the complete article, click here.

For information patients may be interested in, click here.

For more information: www.jvsvenous.org


Related Content

News | Venous Therapies

October 14, 2022 — Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

Home October 14, 2022
Home
News | Venous Therapies

November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral ...

Home November 22, 2021
Home
News | Venous Therapies

February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous ...

Home February 22, 2021
Home
News | Venous Therapies

October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding ...

Home October 26, 2020
Home
News | Venous Therapies

October 31, 2019 – In a large series of iliac vein stent cases, a blinded comparison found intravascular ultrasound ...

Home October 31, 2019
Home
Technology | Venous Therapies

May 6, 2019 — The U.S Food and Drug Administration (FDA) has cleared the Boston Scientific Vici Venous Stent System for ...

Home May 06, 2019
Home
Technology | Venous Therapies

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous ...

Home April 03, 2019
Home
News | Venous Therapies

August 8, 2018 — Boston Scientific Corp. announced it has signed an agreement to acquire Veniti Inc., which has ...

Home August 08, 2018
Home
Feature | Venous Therapies | Tif Siragusa, M.D.

The introduction of thermal ablation revolutionized the treatment of varicose veins, yet recurrence remains a stubborn ...

Home April 30, 2018
Home
News | Venous Therapies

January 26, 2018 – Medtronic plc announced the initiation of its investigational device exemption (IDE) study for the ...

Home January 26, 2018
Home
Subscribe Now